Table 1 Patient demographics and baseline characteristics
Scheiner et al., n = 292 | Yang et al., n = 108 | Hatanaka et al., n = 297 | Teng et al., n = 89 | ||
|---|---|---|---|---|---|
Training set, n = 190 | Validation set, n = 102 | ||||
Age, years | 66.2 ± 10.4 | 64.6 ± 11.9 | 57[44.0, 69.0] | 73.0[68.0, 78.0] | 61.3[56.4,67.8] |
Male, n (%) | 153(81%) | 83(81%) | 96(89%) | 243(82%) | 75(84%) |
Etiology | |||||
Viral | 55(29%) | 39(38%) | 95(88%) | 149(50%) | 79(89%) |
Non-viral | 135 (71%) | 63 (62%) | 13(12%) | 148(50%) | 10(11%) |
Child-Pugh A/B/C | 101/72/17 | 72/28/2 | - | 279/-/- | 76/13/- |
ECOG PS | |||||
0 | 88(46%) | 46(45%) | - | 238(80%) | 35(39%) |
≥ 1 | 102(54%) | 56(55%) | - | 59(20%) | 54(61%) |
Lines of systemic therapy | |||||
Front line | 82(43%) | 35(34%) | - | 169(57%) | 49(55%) |
later line | 108(57%) | 67(66%) | - | 128(43%) | 40(45%) |
BCLC stage A/B/C/D | 2/21/149/18 | -/12/88/2 | -/24/82/- | 17/121/155/4 | -/23/66/- |
Patients with complete CRAFITY score | |||||
0 | 53(28%) | 18(32%) | 25(23%) | 147(49%) | - |
≥ 1 | 137(72%) | 38(68%) | 83(73%) | 150(51%) | - |
Type of immunotherapy-based regimen administered | Anti-PD-(L)1 monotherapy or plus bevacizumab/TKI/ramucirumab | Anti-PD-(L)1 monotherapy or plus bevacizumab/TKI/anti-CTL4-4/anti-CD38 | Anti-PD-(L)1 plus lenvatinib | Atezolizumab plus bevacizumab | Atezolizumab plus bevacizumab |
NOS score | 8 | 7 | 7 | 8 | |